Since AMPK signalling reduces de novo lipogenesis and stimulates fat oxidation [37,39], the suppression of the enzyme activity may potentially contribute to the pathogenesis of NAFLD. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatotic liver disease.